Safety effectiveness and immunogenicity of heterologous mRNA1273 boost after prime with Ad26COV2S among healthcare workers in South Africa The singlearm openlabel phase 3 SHERPA study

Simple item page
dc.article.end-page18en
dc.article.start-page1en
dc.citation.doi10.1371/JOURNAL.PGPH.0003260en
dc.contributor.authorN Garretten
dc.contributor.authorT Reddyen
dc.contributor.authorN Yende-Zumaen
dc.contributor.authorA Takalanien
dc.contributor.authorSimone Richardsonen
dc.contributor.authorThandeka Moyo-Gweteen
dc.contributor.authorSharlaa Badal-Faesenen
dc.contributor.authorFaeezah Patelen
dc.contributor.authorE et alen
dc.date.accessioned2025-04-12T14:30:49Z
dc.departmentWITS REPRODUCTIVE HEALTH AND HIV INSTITUTEen
dc.facultyFACULTY OF HEALTH SCIENCESen
dc.identifier.citationDOAJen
dc.identifier.urihttps://hdl.handle.net/10539/44735
dc.journal.titleSafety effectiveness and immunogenicity of heterologous mRNA1273 boost after prime with Ad26COV2S among healthcare workers in South Africa The singlearm openlabel phase 3 SHERPA studyen
dc.journal.volume4en
dc.titleSafety effectiveness and immunogenicity of heterologous mRNA1273 boost after prime with Ad26COV2S among healthcare workers in South Africa The singlearm openlabel phase 3 SHERPA studyen
dc.typeJournal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal Article.pdf
Size:
1.31 MB
Format:
Adobe Portable Document Format
Description:
Bitstream uploaded by REST Client
Download

Collections

Academic Wits Research Outputs (All submissions)